British Journal of Haematology· 2026Q1
RESOLVE to do better
- 0citations
- Q1SCImago
- 2026year
Short summary
The RESOLVE trial's primary endpoint (leg ulcer resolution) was not met, but Voxelotor showed a trend towards improvement and reduced pain, suggesting potential benefits for sickle cell disease patients.
AI-generated from the title and abstract; the full text is not read.
Key points
- The RESOLVE trial did not meet its primary endpoint for leg ulcer resolution in sickle cell disease patients.
- Voxelotor showed a trend towards improved leg ulcer healing.
- Voxelotor significantly reduced leg ulcer pain in patients.
- The commentary suggests the trial design may have influenced the primary outcome.
AI-generated from the title and abstract; the full text is not read.
Abstract
Commentary on: Long Title: Phase 3, randomised, placebo‐controlled trial of Voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE. Br J Haematol (Online ahead of print). doi: 10.1111/bjh.70856 .
The authors' abstract, as published at the source. British Journal of Haematology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Genetics (Medicine)
GeneticsMedicine